Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Lanreotide depot (LAN) for symptomatic control of carcinoid syndrome (CS) in neuroendocrine tumor (NET) patients previously responsive to octreotide (OCT): Subanalysis of patient-reported symptoms from the phase III elect study. Fisher, G. A., Pommier, R. F., Wolin, E. M., Kunz, P. L., Liyanage, N., Lowenthal, S., Mirakhur, B., Shaheen, M. F., Vinik, A. AMER SOC CLINICAL ONCOLOGY. 2017
View details for DOI 10.1200/JCO.2017.35.15_suppl.4088
View details for Web of Science ID 000411895708172